Loading company…
Virobay develops protease inhibitors for conditions including autoimmune diseases, neuropathic pain, liver disease, and cancer.
Founded in 2006 and based in Menlo Park, US, Virobay develops protease inhibitors using a virtual drug discovery model. Its clinical-stage compounds include VBY-036 and VBY-891, with development targeting neuropathic pain and oral psoriasis. In July 2014, the company raised USD 8.000 mn in Series B funding from AbbVie Biotech Ventures, Alta Partners, and others.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in